Merck Profit Boosted by Sales of Covid-19 Pill

Merck & Co. molnupiravir Covid-19 pills. — Merck & Co. molnupiravir Covid-19 pills.
Source: Merck & Co.

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Take our Survey

April 28, 2022 at 10:48 AM UTC

Updated on

April 28, 2022 at 1:55 PM UTC

This article is for subscribers only.

Merck & Co. reported stronger-than-expected first-quarter profit and revenue and raised its full year outlook Thursday, buoyed by sales of its Covid-19 antiviral following the winter omicron wave.